Chengdu Olymvax Biopharmaceuticals Inc. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 284.76 million compared to CNY 200.09 million a year ago. Revenue was CNY 284.76 million compared to CNY 200.09 million a year ago.

Net income was CNY 77.67 million compared to CNY 36.13 million a year ago. Basic earnings per share from continuing operations was CNY 0.2053 compared to CNY 0.0991 a year ago. Diluted earnings per share from continuing operations was CNY 0.2053 compared to CNY 0.0991 a year ago.